Etanercept for treatment of psoriasis and psoriatic arthritis
HAYES, Inc.
Record ID 32006001080
English
Authors' objectives:
Etanercept consists of two molecules of the human p75 tumor necrosis factor-# (TNF-#) receptor joined to the Fc portion of the human immunoglobulin G1 (IgG1). It binds soluble TNF-# with high specificity and affinity, preventing it from binding to the cell surface receptors (TNF-# receptors) on keratinocytes, thereby inhibiting its proinflammatory effects. It is prescribed as a subcutaneous monotherapy in adults with moderate to severe psoriasis who are candidates for systemic therapy or phototherapy. It is also prescribed, either alone or in combination with methotrexate, in patients with psoriatic arthritis.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.hayesinc.com/
Year Published:
2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Arthritis, Psoriatic
- Immunoglobulin G
- Psoriasis
- Receptors, Tumor Necrosis Factor
- Etanercept
- Treatment Outcome
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
HAYES, Inc.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.